CG Oncology Earnings Call Transcripts
Fiscal Year 2026
-
Healthpeak completed the Janus carve-out and IPO, unlocking value and positioning both REITs for growth. Outpatient medical and lab real estate remain core, with strong demand, strategic acquisitions, and robust cash flow. Janus is set for rapid expansion, leveraging favorable senior housing trends.
-
Credo demonstrates strong efficacy and durability in multiple bladder cancer settings, with a 75.5% CR rate in BOND-003 and promising adjuvant and combination data. Regulatory filings are underway, with commercial launch preparations targeting a concentrated market and leveraging a robust team.
-
The session highlighted strong clinical progress for a novel bladder-sparing immunotherapy, with pivotal trials in both high-risk and intermediate-risk NMIBC nearing key data readouts. The therapy shows best-in-class efficacy, safety, and commercial readiness, with regulatory submissions and market expansion planned through 2027.
Fiscal Year 2025
-
The session highlighted strong two-year response and durability data for CReDO in BCG-unresponsive NMIBC, a robust regulatory and manufacturing strategy, and plans to establish CReDO as backbone therapy across multiple bladder cancer segments. Upcoming pivotal data and a solid cash position support future growth.
-
Significant progress was reported in late-stage clinical trials for NMIBC, including strong 24-month efficacy data and accelerated trial enrollment. Regulatory and manufacturing strategies are focused on CMC readiness and streamlined administration, while commercial plans target unmet needs in high-volume centers.
-
Significant progress in non-muscle invasive bladder cancer with strong clinical data, streamlined administration, and a robust commercial strategy targeting high-volume accounts. BLA filing is on track for year-end, supported by a solid cash position and multiple upcoming data readouts.
-
Cretostimogene demonstrated strong durability and tolerability in high-risk NMIBC, with 46% 12-month and 34% 24-month CR rates, and 97.3% cystectomy-free survival at 24 months. Regulatory filing is planned for H2 2025, and the company is well-financed through 2028.
-
Phase 3 data for cretostimogene in high-risk BCG-unresponsive non-muscle-invasive bladder cancer show a 75.5% complete response rate, class-leading durability, and a favorable safety profile. The therapy is easily administered, with ongoing trials in additional settings and combinations.
-
Focused on bladder-sparing therapies for NMIBC, the program shows strong efficacy, durability, and safety, with a robust regulatory and commercial strategy targeting a large, concentrated U.S. market. Multiple pivotal data readouts and a BLA submission are expected later this year.
Fiscal Year 2024
-
BOND-003 phase 3 results show cretostimogene grenadenorep achieved a 74.5% complete response rate in BCG-unresponsive, high-risk NMIBC, with durable responses exceeding 27 months and a favorable safety profile. Efficacy was consistent across subgroups, and the therapy integrates easily into clinical practice.
-
Cretostimogene shows high response and safety in bladder cancer, with pivotal data expected year-end. Manufacturing and logistics improvements support broad adoption, while new trials address unmet needs due to BCG shortages. Key regulatory and investor focus is on durable response and safety.